2月6日 - ** 生物技术公司TG Therapeutics TGTX.O股价盘前上涨2.7%至28.51美元
** 公布了多发性硬化症疗法Briumvi的新发现，该疗法可治疗一种复发性神经疾病
** 多发性硬化症是一种自身免疫性神经疾病，免疫系统会攻击神经周围的保护膜，破坏大脑和身体之间的信号传递
** 更新内容包括实际数据以及对儿童和青少年的研究
** 最常见的副作用是输液反应和呼吸道感染；5% 的患者出现严重感染
** 2025 年股价小幅下跌
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.